Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | CHUK | O15111 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | NNMT | P40261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13828345 | 0.83 | GFER (0.30) | GFERPOLB | |
| SCHEMBL13828336 | 0.83 | GFER (0.33) | GFERPOLBCCNA2CDK2 | |
| SCHEMBL13828406 | 0.83 | POLB (0.33) | GFERPOLBNNMT | |
| SCHEMBL13828346 | 0.81 | LMNA (0.37) | POLBNNMT | |
| SCHEMBL15868896 | 0.79 | MEN1 (0.33) | — | |
| SCHEMBL15868912 | 0.79 | KDM4E (0.38) | PDPK1HSP90AB1GFER | |
| SCHEMBL13766483 | 0.79 | PDPK1 (0.50) | PDPK1HSP90AB1POLBCCNA2CDK2 | |
| SCHEMBL18704234 | 0.75 | PDPK1 (0.43) | PDPK1HSP90AB1POLBCCNA2CDK2 | |
| SCHEMBL13828430 | 0.72 | HSPA8 (0.38) | PDPK1PIK3CDNNMT | |
| SCHEMBL15817068 | 0.71 | POLB (0.47) | PDPK1HSP90AB1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2018-04-26 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-9775841-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2017-10-03 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885HSP90AB1 509/4885PTPN1 762/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885HSP90AB1 509/4885PTPN1 762/4885 |
| US-20180110783-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | PDPK1 9/4885HSP90AB1 509/4885PTPN1 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.